535 related articles for article (PubMed ID: 31926283)
1. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
[TBL] [Abstract][Full Text] [Related]
2. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
García-Fernández S; García-Castillo M; Bou G; Calvo J; Cercenado E; Delgado M; Pitart C; Mulet X; Tormo N; Mendoza DL; Díaz-Regañón J; Cantón R;
Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
[TBL] [Abstract][Full Text] [Related]
3. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of Pseudomonas aeruginosa recovered in Portugal from low respiratory tract infections in ICU patients (STEP Study).
Hernández-García M; García-Fernández S; García-Castillo M; Pássaro L; Cantón R;
FEMS Microbiol Lett; 2021 Aug; 368(15):. PubMed ID: 34347078
[TBL] [Abstract][Full Text] [Related]
5. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
[TBL] [Abstract][Full Text] [Related]
6. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
Hernández-García M; García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Costa E; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Pássaro L; Paixão L; Romano J; Cantón R;
Int J Antimicrob Agents; 2021 Feb; 57(2):106259. PubMed ID: 33310115
[TBL] [Abstract][Full Text] [Related]
7. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
Seifert H; Körber-Irrgang B; Kresken M;
Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
[TBL] [Abstract][Full Text] [Related]
11. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
[TBL] [Abstract][Full Text] [Related]
12. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
[TBL] [Abstract][Full Text] [Related]
13. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.
Hernández-García M; García-Castillo M; García-Fernández S; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Romano J; Pássaro L; Paixão L; López-Mendoza D; Díaz-Regañón J; Cantón R;
J Antimicrob Chemother; 2021 Jan; 76(2):370-379. PubMed ID: 33099623
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Lob SH; Kazmierczak KM; Chen WT; Siddiqui F; DeRyke CA; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2022 Jun; 29():527-533. PubMed ID: 34896336
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Cantón R; Loza E; Arcay RM; Cercenado E; Castillo FJ; Cisterna R; Gálvez-Benítez L; González Romo F; Hernández-Cabezas A; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
Rev Esp Quimioter; 2021 Jun; 34(3):228-237. PubMed ID: 33645948
[TBL] [Abstract][Full Text] [Related]
18. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
19. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
BMC Microbiol; 2021 Mar; 21(1):74. PubMed ID: 33676406
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]